Drug Trial Radar · NCT04656418
CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks
Last checked: Nov 20, 2026Latest source record: Jun 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Jan 27, 2021
Primary completion
Jun 7, 2022
Study completion Jun 7, 2022
Sponsor
- Lead sponsor
- CSL BehringIndustry
- Sponsor type
- Industry
- First posted
- Dec 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, double-blind, randomized, placebo-controlled, parallel-arm study to investigate the efficacy and safety of subcutaneous administration of CSL312 (garadacimab) in the prophylactic treatment of hereditary angioedema.
Conditions
- Hereditary Angioedema
Interventions
CSL312Biological
Fully human immunoglobulin G subclass 4/lambda recombinant monoclonal antibody
PlaceboDrug
Buffer without active ingredient
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time-Normalized Number of Hereditary Angioedema (HAE) Attacks Per Month During Treatment PeriodTime frame: First injection up to 6 months
Locations
28 sites in 7 countries. Site status is shown where the registry gives one.
Clinical Research Center of Alabama
Birmingham, Alabama
Medical Research of Arizona
Scottsdale, Arizona
Raffi Tachdjian MD, Inc.
Santa Monica, California
Allergy and Asthma Clinical Research
Walnut Creek, California
Institute of Asthma and Allergy
Chevy Chase, Maryland
Bernstein Clinical Research Center LLC
Cincinnati, Ohio
Pennsylvania State University
Hershey, Pennsylvania
AARA Research Center
Dallas, Texas
Clinique specialisee en allergie de la Capitale
Québec, Canada
University of Alberta - Research Transition Facility
Edmonton, Alberta, Canada
Ottawa Allergy Research Corp
Ottawa, Ontario, Canada
Gordon Sussman Clinical Research Inc.
Toronto, Ontario, Canada
Charité Universitätsmedizin Berlin
Berlin, Germany
Universitätsklinikum Leipzig
Leipzig, Germany
CRC Clinical Research / Hautklinik und Poliklinik der Universitätsklinik Mainz
Mainz, Germany
HZRM Hämophilie Zentrum Rhein Main GmbH
Mörfelden-Walldorf, Germany
Universitätsklinikum Frankfurt Goethe-Universität
Frankfurt am Main, Hesse, Germany
Semmelweis University
Budapest, Hungary
Barzilai University Medical Center
Ashkelon, Israel
Saiyu Soka Hospital
Saitama, Japan
Hiroshima University Hospital
Hiroshima, Hiroshima, Japan
Kobe University Hospital
Kobe, Hyōgo, Japan
St.Marianna University School of Medicine Hospital
Kawasaki-shi, Kanagawa, Japan
Saitama Medical Center
Saitama, Kawagoe-shi, Japan
Saga University Hospital
Saga, Saga-shi, Japan
Koga Community Hospital
Yaizu-shi, Shizuoka, Japan
Juntendo University Hospital
Bunkyo, Tokyo, Japan
Amsterdam UMC, Location AMC
Amsterdam, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.